trending Market Intelligence /marketintelligence/en/news-insights/trending/oAF2QCNGnWyYncrdmZLw-A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Turning Point Therapeutics plans $100M IPO to develop cancer therapies

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Turning Point Therapeutics plans $100M IPO to develop cancer therapies

Turning Point Therapeutics Inc. plans to raise up to $100 million in an IPO.

The San Diego-based clinical-stage biopharmaceutical company, founded in 2013, filed to list its common stock on the Nasdaq Global Market under the ticker TPTX.

Turning Point expects to use net proceeds from the offering to further develop in a planned mid-stage study its drug, TPX-0005, also called repotrectinib, for treating certain patients with non-small cell lung cancer and advanced solid tumors. The company will also use proceeds to further develop preclinical candidates, including TPX-0046 and TPX-0022 to treat certain advanced solid tumors.

Goldman Sachs & Co. LLC, SVB Leerink, Wells Fargo Securities and Canaccord Genuity act as underwriters in the transaction.